# An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis

> **NCT02518620** · PHASE2 · COMPLETED · sponsor: **Ablynx, a Sanofi company** · enrollment: 406 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** ALX-0061

## Key facts

- **NCT ID:** NCT02518620
- **Lead sponsor:** Ablynx, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2018-08
- **Final completion:** 2018-08
- **Target enrollment:** 406 (ACTUAL)
- **Last updated:** 2019-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02518620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02518620, "An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02518620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*